Janus Henderson Group
PCVX icon

Janus Henderson Group’s Vaxcyte PCVX Stock Holding History

Janus Henderson Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$960M Buy
16,575,875
+3,188,687
+24% +$173M 0.46% 40
2025
Q4 		$618M Buy
13,387,188
+282,985
+2% +$12.7M 0.28% 83
2025
Q3 		$472M Sell
13,104,203
-1,587,141
-11% -$52.6M 0.22% 107
2025
Q2 		$478M Buy
14,691,344
+2,925,863
+25% +$95.9M 0.23% 104
2025
Q1 		$816M Buy
11,765,481
+1,190,118
+11% +$95.2M 0.45% 39
2024
Q4 		$866M Sell
10,575,363
-346,533
-3% -$34.4M 0.44% 38
2024
Q3 		$1.25B Buy
10,921,896
+2,052,989
+23% +$185M 0.64% 21
2024
Q2 		$670M Buy
8,868,907
+1,195,039
+16% +$81.3M 0.36% 57
2024
Q1 		$524M Buy
7,673,868
+692,492
+10% +$48M 0.29% 88
2023
Q4 		$438M Sell
6,981,376
-79,212
-1% -$4.11M 0.26% 101
2023
Q3 		$360M Buy
7,060,588
+837
+0% +$41.3K 0.24% 112
2023
Q2 		$353M Sell
7,059,751
-67,860
-1% -$3.22M 0.22% 116
2023
Q1 		$267M Buy
7,127,611
+1,153,472
+19% +$48.9M 0.18% 137
2022
Q4 		$286M Sell
5,974,139
-3,101,363
-34% -$122M 0.2% 125
2022
Q3 		$218M Buy
9,075,502
+4,851,015
+115% +$123M 0.08% 224
2022
Q2 		$91.9M Sell
4,224,487
-105,277
-2% -$2.44M 0.06% 265
2022
Q1 		$105M Buy
4,329,764
+83,100
+2% +$1.82M 0.05% 311
2021
Q4 		$101M Buy
4,246,664
+153,198
+4% +$3.56M 0.04% 354
2021
Q3 		$104M Sell
4,093,466
-23,493
-0.6% -$569K 0.05% 355
2021
Q2 		$92.7M Sell
4,116,959
-113,348
-3% -$2.32M 0.04% 388
2021
Q1 		$83.5M Buy
4,230,307
+33,529
+0.8% +$844K 0.04% 421
2020
Q4 		$108M Buy
4,196,778
+349
+0% +$13K 0.05% 340
2020
Q3 		$200M Sell
4,196,429
-529,363
-11% -$21.1M 0.1% 199
2020
Q2 		$140M Buy
+4,725,792
New +$152M 0.08% 249

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group's PCVX Position: Q1 2026 in Review

Janus Henderson Group increased its Vaxcyte (PCVX) stake by 24% in Q1 2026, buying an estimated $173M and bringing the position to 16,575,875 shares worth $960M. The position accounts for 0.46% of the portfolio, ranked #40.

Janus Henderson Group first reported a position in PCVX in Q2 2020 and has held it in 24 quarters since. The position peaked at $1.25B in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Janus Henderson Group held 16,575,875 shares of Vaxcyte worth $960M as of Q1 2026.
  • Janus Henderson Group bought 3,188,687 Vaxcyte shares in Q1 2026, an estimated $173M.
  • Vaxcyte made up 0.46% of Janus Henderson Group's portfolio in Q1 2026, its #40 holding.
  • Janus Henderson Group first reported a position in Vaxcyte in Q2 2020 and has held it in 24 quarters since.
  • Janus Henderson Group's Vaxcyte position peaked at $1.25B in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.